BioSpace News Archive

Daiichi Sankyo Company announced that updated phase 1 safety and efficacy data for trastuzumab deruxtecan, an investigational HER2 were presented for a subgroup of patients with heavily pretreated HER2 mutated or HER2 expressing non-small cell lung cancer

ABEC’s Custom Single Run (CSR®) systems to enhance Emergent BioSolutions’ manufacturing productivity, flexibility and economies of scale

SpinalCyte, LLC today announced it will be showcasing its fibroblast-based cell therapy product CybroCell at the North American Spine Society (NASS) 2018 Annual Meeting Sept. 26 - 29 in Los Angeles.

Funds advised by Apax Partners (the “Apax Funds”) today announced the acquisition of Authority Brands, a leading North American franchisor of home services, from PNC Riverarch Capital. The financial terms of the transaction were not disclosed.

Nonprofit Brings on Industry Leaders Amgen, BTG, EdgeOne Medical, Fujikura, HOYA, NIPRO, Nordson Medical, and W.L. Gore

Gift to establish Gina Cody School of Engineering and Computer Science will improve access to education, fund research and inspire a new generation

In a letter to Attorney General Jeff Sessions, President-elect Marilyn Singleton, M.D., J.D., explains why the Association of American Physicians and Surgeons (AAPS) opposes the proposed merger of CVS and Aetna.

OncLive®, the leading digital provider of resources and information to oncology professionals, in conjunction with The Ruesch Center for the Cure of Gastrointestinal Cancers, will honor five outstanding individuals for their commitment to improving the lives of patients affected by gastrointestinal cancer.

Syndax Pharmaceuticals Inc., Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated results from the ongoing ENCORE 601 cohort enrolling non-small cell lung cancer (NSCLC) patients previously treated with both chemotherapy and PD-(L)1 therapy.

Revance Therapeutics, Inc., (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Cantor Fitzgerald 2018 Global Healthcare Conference in New York, NY.